Literature DB >> 23233563

In elderly patients with AML, which patients should be considered fit or unfit for standard induction therapy?

Ronan Swords1, Valeria Santini.   

Abstract

A 75-year-old man visits his primary care physician for a routine checkup and a complete blood count reveals pancytopenia. BM examination confirms the diagnosis of acute myeloid leukemia. No dysplastic features were noted and his karyotype results are pending. The patient has well-controlled hypertension and his last hospital admission was 20 years ago for repair of a rotator cuff injury. His Eastern Cooperative Oncology Group performance status is 0/4 and he has no cognitive impairment. You believe the patient is fit for standard acute myeloid leukemia induction, but you are concerned because of his older age and you are considering less-intensive approaches.

Entities:  

Mesh:

Year:  2012        PMID: 23233563     DOI: 10.1182/asheducation-2012.1.74

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  5 in total

1.  Prognostic value of the expression of phosphatase and tensin homolog and CD44 in elderly patients with refractory acute myeloid leukemia.

Authors:  Xiao Huang; Dongyun Li; Tiantian Li; B O Zhao; Xinyi Chen
Journal:  Oncol Lett       Date:  2015-05-06       Impact factor: 2.967

2.  Validation of the Khorana score in acute myeloid leukemia patients: a single-institution experience.

Authors:  Abu-Sayeef Mirza; Seongseok Yun; Najla Al Ali; Hannah Shin; Joseph Luke O'Neil; Maher Elharake; Daniel Schwartz; Katherine Robinson; Ethan Nowell; Grace Engle; Ibraahim Badat; Thomas Brimer; Amra Kuc; Ashton Sequeira; Sabbir Mirza; Dhiraj Sikaria; Jesus Diaz Vera; Noah Hackney; Sammy Abusrur; Jose Jesurajan; Jameson Kuang; Shreyans Patel; Sabrina Khalil; Sonya Bhaskar; Alexander Beard; Toaa Abuelenen; Kevin Ratnasamy; Nathan Visweshwar; Rami Komrokji; Michael Jaglal
Journal:  Thromb J       Date:  2019-07-02

3.  A new tool for comprehensive geriatric assessment in elderly patients with acute myeloid leukemia: a pilot study from China.

Authors:  Chun-Li Zhang; Ru Feng; Jiang-Tao Li; Ting Wang; Jie-Fei Bai; Hui Liu
Journal:  Chin Med J (Engl)       Date:  2020-02-20       Impact factor: 2.628

Review 4.  Targeting Approaches of Nanomedicines in Acute Myeloid Leukemia.

Authors:  Xiao Huang; Hai Lin; Feng Huang; Yuning Xie; Ka Hong Wong; Xiaoyu Chen; Dongyue Wu; Aiping Lu; Zhijun Yang
Journal:  Dose Response       Date:  2019-12-11       Impact factor: 2.658

5.  Physician's Attitude Towards Treatment of Older Patients and the Choice of Therapy.

Authors:  Felicetto Ferrara
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-04-10       Impact factor: 2.576

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.